Caleb Hulme-Moir

Life science researchers and entrepreneurs encouraged to seek investment from new $40m Australian biotech incubator

The MRCF, managed by publisher Brandon Capital, has launched a government-funded national biotech incubator with committed funding, and appointed a new Head of Operations, with applications now open for its first intake.

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments

Brandon Capital led a NZ$14 million investment in Amaroq Therapeutics, a University of Otago spinout developing RNA cancer therapies, with three co-investors and a Callaghan Innovation repayable grant supporting the deal.

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments

University of Otago cancer RNA spinout Amaroq Therapeutics has raised NZ$14 million led by Brandon Capital with Otago Innovation, NZ Innovation Booster and Cure Kids Ventures to advance its lncRNA-targeting cancer therapies.

Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio

Researchers cannot be expected to commercialise their innovations alone says leading IP lawyer and new MRCF Board member

IP lawyer Kylie Diwell joins the board of the Brandon Capital-managed MRCF. She argues research commercialisation needs skilled teams, while MRCF leaders welcome government innovation support and urge patent box tax reform for biotech.